**Oxford Astrazeneca update**
On 7 April 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) issued new advice, concluding a possible link between the AstraZeneca COVID-19 vaccine AstraZeneca and extremely rare, unlikely to occur blood clots. It concluded that the benefits of vaccination continue to outweigh any risks but advised careful consideration be given to people who are at higher risk of specific types of blood clots because of their medical condition.
The Joint Committee on Vaccination and Immunisation (JCVI) has weighed the relative balance of benefits and risks of the AstraZeneca COVID-19 vaccine and advise that:
- the benefits of prompt vaccination with the AstraZeneca COVID-19 vaccine far outweigh the risk of adverse events for individuals 30 years of age and over and those who have underlying health conditions which put them at higher risk of severe COVID-19 disease.
- It is preferable for adults aged under 30 years without underlying health conditions that put them at higher risk of severe COVID-19 disease, to be offered an alternative COVID-19 vaccine, if available. People may make an informed choice to receive the AstraZeneca COVID-19 vaccine to receive earlier protection.
Read more here: Covid-19 vaccinations in Somerset – Somerset CCG